Skip to main content
. 2015 Jan 22;12(3):223–233. doi: 10.7150/ijms.10656

Table 3.

Symmetry analysis: Associations of statins with cancers

Incident
users
Cases with cancer Diagnosis of cancer
last/first
Adjusted SR 95% CI
Lower Upper
A: Colorectal cancer
Statins 38,402 1,575 747 648 1.20 1.08 1.34
Simvastatin 2,118 85 43 32 1.06 0.66 1.73
Rosuvastatin # 17,515 742 311 353 0.95 0.81 1.11
Atorvastatin # 14,359 611 295 256 1.33 1.12 1.57
Fluvastatin 1,678 81 35 37 0.72 0.44 1.18
Pitavastatin # 8,942 381 184 154 1.32 1.06 1.65
Pravastatin 9,327 473 224 195 1.00 0.82 1.22
B: Lung cancer
Statins 38,402 818 396 313 1.32 1.13 1.53
Simvastatin 2,118 42 24 13 1.46 0.72 3.13
Rosuvastatin # 17,515 405 181 177 3.46 2.80 4.28
Atorvastatin # 14,359 312 144 129 1.28 1.01 1.64
Fluvastatin 1,678 48 22 18 0.94 0.48 1.85
Pitavastatin # 8,942 185 87 75 1.28 0.93 1.77
Pravastatin 9,327 225 113 88 1.12 0.84 1.50
C: Pancreatic cancer
Statins 38,402 804 388 293 1.31 1.13 1.53
Simvastatin 2,118 44 17 18 0.71 0.34 1.46
Rosuvastatin # 17,515 386 179 156 1.17 0.94 1.46
Atorvastatin # 14,359 303 147 110 1.47 1.14 1.90
Fluvastatin 1,678 45 22 16 1.00 0.50 2.04
Pitavastatin # 8,942 208 92 92 1.05 0.78 1.42
Pravastatin 9,327 221 113 88 1.07 0.80 1.43
D: Gastric cancer
Statins 38,402 1,333 595 568 1.04 0.93 1.17
Simvastatin 2,118 72 25 37 0.51 0.29 0.87
Rosuvastatin # 17,515 626 257 297 0.89 0.75 1.05
Atorvastatin # 14,359 538 225 239 1.04 0.86 1.25
Fluvastatin 1,678 83 34 40 0.62 0.38 1.01
Pitavastatin # 8,942 307 122 147 0.88 0.69 1.12
Pravastatin 9,327 339 107 80 1.12 0.83 1.51
E: Esophageal cancer
Statins 38,402 125 68 45 1.38 0.93 2.05
Simvastatin 2,118 3 2 1 1.38 0.07 81.45
Rosuvastatin # 17,515 57 32 21 1.42 0.79 2.58
Atorvastatin # 14,359 65 28 30 0.95 0.55 1.64
Fluvastatin 1,678 7 4 2 1.34 0.19 14.76
Pitavastatin # 8,942 38 22 14 1.52 0.74 3.21
Pravastatin 9,327 24 11 9 0.93 0.35 2.55
F: Breast cancer (female)
Statins 15,694 485 195 239 0.81 0.66 0.98
Simvastatin 971 18 4 12 0.25 0.06 0.83
Rosuvastatin # 7,075 227 87 119 0.74 0.56 0.99
Atorvastatin # 5,756 176 68 85 0.90 0.64 1.25
Fluvastatin 756 31 17 11 1.12 0.50 2.65
Pitavastatin # 3,542 118 43 60 0.75 0.49 1.13
Pravastatin 4,283 128 54 63 0.73 0.50 1.07
G: Hematological malignancies
Statins 38,402 373 156 171 0.90 0.72 1.12
Simvastatin 2,118 21 9 12 0.56 0.21 1.44
Rosuvastatin # 17,515 161 68 77 0.89 0.63 1.25
Atorvastatin # 14,359 165 64 84 0.83 0.59 1.16
Fluvastatin 1,678 19 10 9 0.80 0.29 2.22
Pitavastatin # 8,942 80 32 35 0.95 0.57 1.58
Pravastatin 9,327 92 35 47 0.61 0.38 0.97
H: Melanoma
Statins 38,402 34 20 14 1.15 0.55 2.46
Simvastatin 2,118 0 0 0 - - -
Rosuvastatin # 17,515 18 9 9 0.61 0.21 1.72
Atorvastatin # 14,359 13 7 5 1.26 0.35 5.05
Fluvastatin 1,678 2 0 2 0.00 - -
Pitavastatin # 8,942 12 7 5 1.20 0.33 4.78
Pravastatin 9,327 7 4 3 0.90 0.15 6.15
I: Prostate cancer (male)
Statins 22,708 522 231 231 1.16 0.96 1.40
Simvastatin 1,147 33 11 18 0.53 0.23 1.19
Rosuvastatin # 10,440 247 103 119 1.04 0.79 1.36
Atorvastatin # 8,603 229 100 105 1.20 0.90 1.60
Fluvastatin 922 27 13 12 0.92 0.38 2.19
Pitavastatin # 5,400 154 72 67 1.33 0.94 1.88
Pravastatin 5,044 143 66 58 1.08 0.74 1.56

Incident users: Number of patients who received their first prescription for statins

Cases with cancer: Number of patients newly diagnosed with cancer

Diagnosis of cancer last: Diagnosis of cancer last indicates the number of patients with a diagnosis after statin use

Diagnosis of cancer first: Diagnosis of cancer first indicates the number of patients with a diagnosis before statin use

Adjusted SR: Adjusted sequence ratio

CI: Confidence interval

#: High potency statin